Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



THERANEXUS and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate BBDF-101

12/12/2019
Download PDF File (363 Ko)

THERANEXUS reports cash position as of September 30th 2019

15/10/2019
Download PDF File (285 Ko)

THERANEXUS announces its first half 2019 results

26/09/2019
Download PDF File (285 Ko)

A new milestone reached for Theranexus: inclusion of last patient in phase II trial for THN102 in Parkinson’s patients

24/09/2019
Download PDF File (285 Ko)

THERANEXUS announces inclusion of last subject in its phase 1b trial of THN201

17/09/2019
Download PDF File (397 Ko)

December, 2019 : CF&B Midcap Event, Geneva (exact date to be confirmed)